Marked yield of re‐evaluating phenotype and exome/target sequencing data in 33 individuals with intellectual disabilities

The diagnosis of intellectual disability/developmental delay (ID/DD) benefits from the clinical application of target/exome sequencing. The yield in Mendelian diseases varies from 25% to 68%. The aim of the present study was to identify the genetic causes of 33 ID/DD patients using target/exome sequencing. Recent studies have demonstrated that reanalyzing undiagnosed exomes could yield additional diagnosis. Therefore, in addition to the normal data analysis, in this study, re‐evaluation was performed prior to manuscript preparation after updating OMIM annotations, calling copy number variations (CNVs) and reviewing the current literature. Molecular diagnosis was obtained for 19/33 patients in the first round of analysis. Notably, five patients were diagnosed during the re‐evaluation of the geno/phenotypic data. This study confirmed the utility of exome sequencing in the diagnosis of ID/DD. Furthermore, re‐evaluation leads to a 15% improvement in diagnostic yield. Thus, to maximize the diagnostic yield of next‐generation sequencing (NGS), periodical re‐evaluation of the geno/phenotypic data of undiagnosed individuals is recommended by updating the OMIM annotation, applying new algorithms, reviewing the literature, sharing pheno/genotypic data, and re‐contacting patients.

[1]  Xuefan Gu,et al.  Further delineation of the phenotype of truncating KMT2A mutations: The extended Wiedemann–Steiner syndrome , 2017, American journal of medical genetics. Part A.

[2]  A. V. Vulto-van Silfhout,et al.  A novel MED12 mutation: Evidence for a fourth phenotype , 2016, American journal of medical genetics. Part A.

[3]  G. Bejerano,et al.  Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers , 2016, Genetics in Medicine.

[4]  R. Pfundt,et al.  CREBBP mutations in individuals without Rubinstein–Taybi syndrome phenotype , 2016, American journal of medical genetics. Part A.

[5]  Andrea Superti-Furga,et al.  Exome Sequencing and the Management of Neurometabolic Disorders. , 2016, The New England journal of medicine.

[6]  J. Rivière,et al.  Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole‐exome sequencing as a first‐line diagnostic test , 2016, Clinical genetics.

[7]  Clara Gaff,et al.  Patient safety in genomic medicine: an exploratory study , 2016, Genetics in Medicine.

[8]  Gert Matthijs,et al.  Guidelines for diagnostic next-generation sequencing , 2015, European Journal of Human Genetics.

[9]  E. Puffenberger,et al.  Matching Two Independent Cohorts Validates DPH1 as a Gene Responsible for Autosomal Recessive Intellectual Disability with Short Stature, Craniofacial, and Ectodermal Anomalies , 2015, Human mutation.

[10]  D. Valle,et al.  GeneMatcher Aids in the Identification of a New Malformation Syndrome with Intellectual Disability, Unique Facial Dysmorphisms, and Skeletal and Connective Tissue Abnormalities Caused by De Novo Variants in HNRNPK , 2015, Human mutation.

[11]  R. Pauli,et al.  Novel COL2A1 Variant (c.619G>A, p.Gly207Arg) Manifesting as a Phenotype Similar to Progressive Pseudorheumatoid Dysplasia and Spondyloepiphyseal Dysplasia, Stanescu Type , 2015, Human mutation.

[12]  A. Munnich,et al.  Nonsyndromic X-linked intellectual deficiency in three brothers with a novel MED12 missense mutation [c.5922G>T (p.Glu1974His)] , 2015, Clinical case reports.

[13]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[14]  S. Haas,et al.  Clinical and neurocognitive characterization of a family with a novel MED12 gene frameshift mutation , 2013, American journal of medical genetics. Part A.

[15]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[16]  Allyn McConkie-Rosell,et al.  The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders , 2013, Genetics in Medicine.

[17]  K. Boycott,et al.  Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.

[18]  B. V. van Bon,et al.  Mutations in MED12 cause X-linked Ohdo syndrome. , 2013, American journal of human genetics.

[19]  E. Banks,et al.  Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. , 2012, American journal of human genetics.

[20]  Leslie G Biesecker,et al.  Next‐generation sequencing demands next‐generation phenotyping , 2012, Human mutation.

[21]  Wei Chen,et al.  Deep sequencing reveals 50 novel genes for recessive cognitive disorders , 2011, Nature.

[22]  M. Stratton,et al.  The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene , 2007, Journal of Medical Genetics.

[23]  J. Opitz,et al.  A recurrent mutation in MED12 leading to R961W causes Opitz-Kaveggia syndrome , 2007, Nature Genetics.

[24]  Y. Gillerot,et al.  Blepharophimosis‐mental retardation (BMR) syndromes: A proposed clinical classification of the so‐called Ohdo syndrome, and delineation of two new BMR syndromes, one X‐linked and one autosomal recessive , 2006, American journal of medical genetics. Part A.

[25]  H. Leonard,et al.  The epidemiology of mental retardation: challenges and opportunities in the new millennium. , 2002, Mental retardation and developmental disabilities research reviews.